Table 2.
Repeated measure ANCOVA analysis for the SARA and FARS II score changes.
| DF | Sum Square | Mean Square | F value | P | Post-Hoc | |
|---|---|---|---|---|---|---|
| SARA score change | ||||||
| Residuals | 519.9 | 3.7 | – | |||
| Follow-up (months) | 4 | 38.8 | 9.7 | 2.595 | 0.039* | 3 M > baseline*, 3 M > 1 M**, 6 M > 1 M* |
| SARA score at baseline | 1 | 2204.0 | 2204.0 | 589.207 | < 0.001** | – |
| Age (years) | 1 | 17.2 | 17.2 | 4.601 | 0.034* | – |
| Male sex | 1 | 7.8 | 7.8 | 2.077 | 0.152 | |
| Type | 5 | 49.3 | 9.9 | 2.636 | 0.026* | SCA7 > SCA6** |
| Trinucleotide repeat length (long allele) | 1 | 3.8 | 3.8 | 1.009 | 0.317 | – |
| Duration of disease (years) | 1 | 10.4 | 10.4 | 2.786 | 0.097 | – |
| Dosage of nilotinib (mg) | 1 | 11.5 | 11.5 | 3.074 | 0.082 | – |
| FARS II score change | ||||||
| Residuals | 1029.1 | 7.2 | – | |||
| Follow-up (months) | 4 | 75.7 | 18.9 | 2.612 | 0.038* |
1 M, 3 M > Baseline** 6 M, 12 M > Baseline* |
| SARA score at baseline | 1 | 1754.0 | 1754.0 | 242.036 | < 0.001** | – |
| Age (years) | 1 | 58.0 | 58.0 | 8.008 | 0.005** | – |
| Male sex | 1 | 0.2 | 0.2 | 0.028 | 0.867 | |
| Type | 5 | 89.9 | 18.0 | 2.481 | 0.035* | SCA6 > SCA2**, SCA6 > SCA3* |
| Trinucleotide repeat length (long allele) | 1 | 0.3 | 0.3 | 0.044 | 0.835 | – |
| Duration of disease (years) | 1 | 1.6 | 1.6 | 0.214 | 0.644 | – |
| Dosage of nilotinib (mg) | 1 | 1.4 | 1.4 | 0.196 | 0.658 | – |
ANCOVA analysis of covariance, DF degree of freedom, SARA scale for the assessment and rating of ataxia, FARS Rating scale for Friedreich’s ataxia, SCA spinocerebellar ataxia.
*P < 0.05 and **P < 0.01.